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As a country of mega biodiversity, Indonesia is also vulnerable to biopiracy target. To prevent biopiracy, it is crucial to 
protect the country’s genetic resources. In order to protect genetic resources and to prevent biopiracy, Indonesia has 
included the requirement of Disclosure of Origin (DO) in The Indonesian Patents Act, 2016 by imposing patent applicants to 
disclose the origins of genetic resources in Patent application. This paper critically analyses the Patents Act to highlight key 
issues that undermine the country’s efforts to combat biopiracy. The principal findings are that there are significant 
problems with implementing DO provisions of the Act in the fight against bio piracy.  The effectiveness of the legislation 
remains questionable and some important sections of the Act lack clarity. The purported regulatory framework under the Act 
to enforce DO and to help deal with biopiracy is ill defined and human resources are inadequate. The paper concludes that to 
combat biopiracy effectively Indonesia needs to review its legislative and institutional framework on DO and consider 
establishing a National Anti-Biopiracy Commission.   
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Genetic resources (GR) are important in critical areas 
of economic activity for food production, health, and 
poverty reduction. For the agriculture sector, GR are 
essential for agro biodiversity.1 However, the legal 
control and ownership of GR remain a difficult and 
complex issue particularly for developing countries. 
The countries, including Indonesia, rich in 
biodiversity have long struggled to establish 
ownership and maintain sovereign control over their 
GR in order to protect them from biopiracy through 
misappropriation and unfair exploitation, particularly 
by foreign biotechnology-based industries from 
developed countries. The protection of GR is an 
integral element of a state’s sovereignty over its 
natural resources.  But GR is also at the heart of 
several bio-related patents. Developing countries 
consider the current international intellectual property 
(IP) regime that enshrines respect for patents as not 
serving their interests, and is sometimes incompatible 
with the conservation and sustainable use of genetic 
resources. The IP regime in relation to genetic 
resources particularly in Trade Related Aspects of 
Intellectual Property Rights (TRIPS) is seen as largely 
favoring the interests of developed countries that 
generally seek access to GR in developing countries 
sometimes without adequate acknowledgment or 
compensation.2 
The commercial exploitation of naturally occurring 
biochemical or genetic material, without paying fair 
compensation to the community from which it 
originates constitutes biopiracy.1 To prevent 
biopiracy, patent applicants are required to disclose 
the origins of the GR in accordance with the laws of 
the source country. The DO ensures transparency 
within the patent system and facilitates the monitoring 
of genetic resources utilization. In 2016, Indonesia 
enacted the Indonesian Patents Act3 that deals with 
GR and the enforcement of related law. However, the 
implementation of the Act to police and enforce DO 
in the Indonesian patents system has been far from 
effective.  Indonesian policy and laws have lagged 
behind the practice and complexity of biopiracy and 
bioprospecting thus raising questions about the 
effectiveness of the current legal framework.  The 
objective of the article is to critically assess the 
effectiveness of The Patents Act in the country’s 
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effort to combat biopiracy. The paper is divided into 
seven parts.  The first part provides the importance of 
protection of GR that includes Indonesian diversity, 
the importance of GR for Indonesian economy and 
necessitates an effective DO regime to protect GR. 
Part two analyzes sovereignty over natural resources 
to protect GR. Part three discusses the concepts of 
biopiracy and bio-prospecting. Part four overviews 
DO by analyzing the concept, the development, the 
function and the scope of DO. Further, the last part 
analyses the inclusion of DO in Indonesian Patents 
Act followed by the effectiveness of DO to combat 
biopiracy with critical challenges in part six.  Finally 
in part seven, the paper discusses the main findings 
with recommendations.   
 
The Protection of Genetic Resources 
Indonesia’s Mega Biodiversity  
As a tropical archipelago, Indonesia’s territory 
comprises some 17,499 islands with a landmass of 
2.01 million km.2 Its maritime territory covers an area 
of about 5.8 million km2 consisting of 3.25 million 
km2 of territorial waters and 2.55 million km2 of 
Exclusive Economic Zone.  With a coastline of 
80,791 km, and flanked by the Pacific and Indian 
oceans, Indonesia is home to some of the richest 
biodiversity in the world.5 The country’s documented 
species diversity comprises 1,500 species of algae, 
80,000 fungal species, 595 species of lichens, 2,197 
fern species, and 30,000-40,000 of spermatophyte 
species, accounting for 15.5% of the world flora.  It is 
also home to 8,157 fauna species of mammal, bird, 
reptile, fish and 1,900 butterfly species accounting for 
10% of the species on earth.6 
 
The Importance of GR for Indonesian Economy  
For centuries Indonesian communities have 
traditionally exploited genetic resources in plant 
species for their daily needs and crops’ improvement 
through breeding and domestication. Since most 
Indonesians depend on the agricultural sector for 
subsistence and employment, the protection and 
conservation of the country’s biodiversity and GR is 
critical to Indonesia’s socio economic infrastructure.  
To put this in perspective, more than 100 species of 
plants are used as sources of carbohydrate; about 100 
species of leguminous plants for protein and fat; about 
450 species are harvested as fruit trees.  About 1000 
species are used as for ornamental plants, 250 species 
of vegetables for vitamin and mineral sources, 70 
species are used for spices, and 40 species are used 
for beverages; and more than 940 species are used as 
traditional medicinal plants.6 The success of breeding 
and domestication depend heavily on GR diversity as 
the sources of genes. The proper management of GR 
especially plant genetic resources is very important 
for supporting breeding programs and other 
agricultural uses. The effective management of GR is 
also essential for supporting the proper utilization of 
plant genetic resources.  It can help prevent biopiracy, 
ensure sustainability use of genetic resources, and 
accordingly support food security programs.  
GR are essential for agriculture development and 
agro biodiversity. Agriculture in Indonesia is the main 
source of fulfilling domestic food consumption.7  The 
demand of domestic consumers for agricultural 
products has been increasing over the years and its 
growth has largely been attributed to Indonesian per 
capita income growth.8 It is undeniable that 
agriculture is a key factor to the Indonesian economy. 
The agricultural sector has lifted millions out of 
poverty and provided a platform for both rural and 
urban economic growth. For Indonesia, the protection 
of its GR and the need to combat biopiracy are 
therefore essential elements in its economic 
development strategy.    
There is also an urgent need to ensure the security 
and development of GR to underpin Indonesian food 
security because of the vital contribution of GR 
(especially plants GR) for agro business. According to 
Article 1 of 1996 Rome Declaration on World Food 
Security,9 food security exists when all people, at all 
times, have physical and economic access to 
sufficient safe and nutritious food that meets their 
dietary needs and food preferences for an active and 
healthy life. Similarly, The Indonesian Food Act of 
2012 also defines food security as a situation where 
an individual at all times, has physical, social and 
economic access to sufficient, diversified, safe and 
nutritious food that meets his or her dietary needs 
necessary for an active and healthy life.10 However, 
food security should not been seen in terms of the 
ability to access to food alone.  Food security systems 
and strategies also involve interrelated subsystems 
that include production, process, distribution, and the 
consumption of food.11 These in turn are determined 
by availability and the production of seeds and control 
over plant materials.12 
 
The Necessity of GR Protection 
The protection of GR in Indonesia is as complex as 
the vastness of its territory and its intricate mega 




biodiversity. The problem for the country is how to 
balance the imperative of sovereign control of GR 
while still promoting and encouraging national and 
international research and development based on its 
rich biodiversity. The adoption of the Indonesian 
Patents Act with its provisions on DO was meant to 
address the balance between the competing demands 
of sovereignty over GR and the need to protect the 
national interest on the one hand, and the attraction of 
the country’s mega biodiversity for international 
research and development and potential patent 
applicants for the benefit of mankind. To understand 
the issues with the Indonesian Patents Act it is first 
necessary to examine the concepts of biopiracy and 
bio prospecting that necessitate DO to protect the 
country’s GR. 
DO has become a critical issue in the modern era of 
biotechnology advancements where pharmaceutical 
and agricultural companies make extensive use of the 
patent system and rely on their research and 
development (R&D) based on naturally occurring 
materials or GR. They hunt and study GR, exploring 
opportunities to develop new products, techniques and 
applications. However, questions about fair and 
equitable access arise when no authorization for 
access to the resources, and no compensation is paid 
to local communities for their contribution in R&D 
activities, and when an invention developed from 
genetic resources is patented. For developing 
countries such as Indonesia that are rich in 
biodiversity, the international regime of DO provides 
an important avenue for protecting national 
sovereignty over GR.   
 
The Principle of Sovereignty over Natural Resources 
to Protect GR 
Genetic Resources and the Sovereignty over Natural 
Resources  
Prior to the CBD, genetic resources were regarded 
as a common good and part of the common heritage 
of mankind. The international customary law notion 
that genetic resources were res nullius led to the 
impression that genetic resources were “(…) 
something over which everybody and, at the same 
time, nobody had rights”.13 Under this notion, 
everybody and nobody specifically have the right to 
access and use genetic resources. The state (of 
origins’) right could only be understood within the 
context of everybody’s right.14 That meant that States 
in whose territories the genetic resources found have 
the right to use the genetic resources, but not to 
regulate any genetic resources related to activities of 
other States in their territories. 
The first international agreement to recognize 
states’ sovereign rights with respect to plant genetic 
resources was the FAO International Undertaking on 
Plant Genetic Resources, as clarified by Resolution 
3/91, which endorsed the concept that “nations have 
sovereign rights over their plant genetic resources.15 
This principle means that a state has the power and 
jurisdiction to establish how the resources and assets 
(tangible and intangible) existing in its territory are 
distributed, used and eventually subject to property 
rights. However, the FAO undertaking limits such 
rights by allowing access to samples of plant genetic 
resources only for specified purposes (scientific 
research, plant breeding or conservation). The 
undertaking clearly excludes access with the aim to 
reproduce the materials for commercial purposes, 
such as for propagating seeds.16 
The CBD went a step further by establishing rules 
of a binding nature, applied to resources held in their 
natural habitats. The FAO also adopted the 
International Code of Conduct for Plant Germplasm 
Collection and Transfer17 that included rules on the 
granting of collectors’ permits and on the 
responsibilities of collectors, sponsors, curators and 
users of plant germplasm. Progressively, the CBD 
brought about more significant changes when Article 
15 not only recognized the sovereign rights of states 
over their natural resources, but also their authority to 
determine access to genetic resources and benefit 
sharing subject to their national legislations. While 
the res nullius doctrine did not clearly delineate the 
rights of states over genetic resources, the CBD came 
to advocate a right states never had before: the 
sovereign right over genetic resources in their 
jurisdiction and determining the related rules of 
access and other conditions (Article. 15.1). Under the 
CBD, not only were states obliged to respect the need 
for their biogenetic resources to be made available for 
humankind, but they were also required to respect the 
right of a significant other class of stakeholders such 
as indigenous peoples cultivating or breeding  
the genetic resources.  It must however be noted  
that under the terms of the CBD the right to  
protect genetic resources is not meant to be a tool 
against access since it is contrary to the  
CBD objectives to illegitimately restrict access to 
genetic resources.18 




As a CBD party, Indonesia is required under the 
CBD framework to enact laws domestically in order 
to give effect to the principles and commitments in 
the CBD including provision related to access and 
benefit sharing. Based on the right to regulate, genetic 
resources are managed and controlled by Indonesia as 
sovereign custodian. According to Article 15.2 of the 
CBD, Indonesia has the sovereign right to regulate 
access to genetic resources in its territories and is 
encouraged to tailor measures that facilitate access 
and sustainable use of genetic resources, as well as 
promote benefit sharing from utilized genetic 
resources (Article 15.7). This requires appropriate 
legislative, administrative and policy measures 
(Article 15.7). Genetic resources users in turn are 
obliged to compensate suppliers for appropriation of 
these resources and to share benefits from utilized 
resources either in monetary or non-monetary form.  
They are also required to provide DO of the genetic 
resources based on the Bonn Guidelines and  
Nagoya Protocol.  
 
GR and Indonesia’s Sovereignty over Natural Resources  
The sovereignty of Indonesia over its natural 
resources is acknowledged under Article 33.3 of 
Indonesian Constitution 1945 which states that the 
land, the waters and the natural resources within 
Indonesia shall be under the powers of the State and 
shall be utilized for the greatest benefit and social 
welfare of the Indonesian people.  With specific 
references to plant genetic resources, the country’s 
sovereignty has been recognized under the Indonesian 
Plant Variety Protection Act of 2000 which provides 
that local plant varieties owned by the community 
shall be under the control of the State (Article 7.1). 
Such control of the State referred to in paragraph 
Article 7.1 shall be implemented by the Government 
(Article 7.2). The government is responsible for 
giving denomination to the local varieties (Article 
7.3). Provisions relating to the denomination of the 
variety, registration, and the use of local variety as 
well as the agency that is given the implementation 
task shall be further regulated by the Government 
(Article 7.4). 
Sovereignty over genetic resources is further 
reflected in the 2017 Ministerial Regulation released 
by the Research and Technology and Higher 
Education Ministry.  The regulation aims to prevent 
biopiracy. It stipulates that the government will no 
longer provide recommendations for foreign 
researchers to conduct research in less-explored 
regions prone to natural resources theft such as Papua 
and Maluku islands.19 While the regulation does not 
impose a total ban on research in those areas, it makes 
it more difficult for foreign scientists to obtain a 
permit for research there. Indonesia allows local 
researchers first to conduct research in areas where 
new species of flora and fauna have been found.  
The 2017 ministerial regulation was  a response to 
the threat of biopiracy in Indonesia.  It also aims to 
fight a more subtle form of biopiracy that occurs 
through unfair research cooperation agreements 
between local and foreign scientists. The 
government’s free-visa policy for 169 countries -
aimed at boosting foreign tourist arrivals in Indonesia-
has made it easier for foreigners to access Indonesian 
local genetic resources under the guise of tourism. 
There are concerns that foreign ‘tourists’ are 
prospecting, developing and exploiting local genetic 
resources without obtaining consent or relevant 
permits from authorities or providing fair 
compensation to Indonesia as stipulated in the Nagoya 
Protocol.20 All these factors necessitate a rigorous and 
coherent patent governance system that incorporates a 
well policed regime of DO in Indonesia as a necessary 
anti biopiracy strategy.  
 
Biopiracy and Bio prospecting of GR 
Biopiracy 
One of the functions of DO is to eliminate 
biopiracy. The term biopiracy is used to describe 
misappropriation of indigenous people’s knowledge 
and biocultural resources, especially through the use 
of IP schemes.21 The term implies negative 
connotations.  Accordingly some prefer the neutral 
phrase “appropriation without benefit sharing”.22 
Although there are no authoritative definitions for 
the term of biopiracy, it is generally defined as 
unauthorized use of biological resources or traditional 
knowledge, unequal shares of benefits, or patenting 
without respect to substantive patent law criteria. 
Graham Dutfield defines biopiracy as “theft, 
misappropriation of, or unfair free riding” or 
“unauthorized and uncompensated collection [of GR] 
for commercial ends.”23  Vandana Siva refers to 
biopiracy as the use of IP systems to legitimize the 
exclusive ownership and control over biological 
resources and biological products that have been used 
over centuries in non-industrialized countries.24 
Biopiracy includes elements such as the acquiring of 




exclusive monopoly control through use of 
intellectual property and in particular patenting, and 
the lack of prior informed consent for the 
transaction.25  Biopiracy is essentially the patenting of 
(often spurious) inventions based on biological 
resources and/or traditional knowledge that are 
extracted without adequate authorization and benefit 
sharing from other (usually developing countries), 
indigenous or local communities.26 
Common patterns of biopiracy cases reflect 
commodification accompanied by patenting of 
promising genetic resources from the developing 
world. The world’s first case against biopiracy was a 
patent taken out by WR Grace and Co in the well-
known Neem Tree of India (EPO Patent 436257 B1), 
which was famously revoked in 2000 after 
community opposition on the grounds of lack of 
novelty and inventive steps.27 Another famous case 
was a USA patent held by University of Mississippi 
(US Pat No. 5401, 504) for turmeric powder which 
was a well-known wound-healing medicine in India, 
and which was successfully revoked on the ground 
that the plant used was common knowledge in India. 2  
In Indonesia, the Shiseido case became a famous 
biopiracy incident in which the Japanese cosmetic 
Shiseido patented 11 different compounds of 
Indonesian traditional medicinal plants or “Jamu”, 
and after launching a campaign against the claim, 
Shiseido withdrew its patent at the European Patent 
Office.27 
Cases of biopiracy are most commonly associated 
with the granting of a patent over some product or 
derivative from genetic resources and/or traditional 
knowledge. Incidents of biopiracy and genetic 
resources misappropriation have been triggered by the 
strengthening of IP systems in developed countries 
and the expansion of IP protection to biological 
materials and their derivatives.28 The rise of an 
aggressive biotechnology industry using genetic 
resources in developed countries has also played a 




In the early 1990s bio prospecting became a 
political talking point when less developed countries 
perceived injustice because the benefits from those 
inventions were not passed on to them. The origins of 
the term bio prospecting are associated with the 1993 
book Biodiversity Prospecting by Reid et al., where it 
was defined as the exploration of biodiversity for 
commercially valuable genetic and biochemical 
resources.30 The term bio prospecting has come to be 
used to positively portray the collection of biological 
specimens for scientific research and/or 
commercialization, in contrast to biopiracy.31 Bio 
prospecting is defined as where parties from more 
economically developed countries travel to less 
developed countries with high biodiversity, and seek 
natural source materials from which to develop drugs 
and other inventions. Bio prospecting involves 
searching for, collecting, and deriving genetic 
materials from biodiversity samples that can be used 
in commercialized pharmaceutical, agricultural, 
industrial, or chemical processing end products.32 
To address bio prospecting and biopiracy, the 
World Intellectual Property Organization (WIPO) and 
CBD, proposed mandatory a requirement to disclose - 
in relevant patent applications - the source of genetic 
resources used in the invention, and the source 
countries that would have the right to some share of 
the profit from the invention. This provided the 
foundations to implement DO in a legally binding and 
universal manner by facilitating a global and 
compulsory system of disclosure and access and 
benefit sharing (ABS) as a level playing field for 
commercial exploitation of patents derived from 
genetic resources under Article 15(7) of the CBD. 
 
Disclosure of Origin 
The Concept of Disclosure of Origin 
In general terms, DO refers to the obligation, 
included mainly in genetic resources access laws, to 
disclose the country of origin or source of genetic 
resources used in an invention, or to demonstrate the 
legality of access to the resources.32 This obligation 
may also include evidence of the existence of prior 
informed consent, the fair and equitable sharing of the 
benefits, and compliance with national law regarding 
access to the genetic resource or traditional 
knowledge.32 DO is thus a critical element in 
intellectual property applications, product approval 
and the monitoring access to and utilization of genetic 
resources and traditional knowledge.33 
 
The Development of DO  
DO was introduced formally at the sixth 
Conference of Parties (COP) to the Convention on 
Biological Diversity (CBD) in 2002.  The COP 
adopted the Bonn Guidelines as voluntary guidelines 




to address access to genetic resources and fair and 
equitable benefit sharing arising from use of genetic 
resources.34 The Bonn Guidelines encourage national 
governments to oblige patent applicants to disclose 
the country of origin of genetic resources and the 
origin of traditional knowledge, innovations and 
practices of indigenous and local communities 
embodying traditional lifestyles (traditional 
knowledge), when the subject matter of the 
application concerns or makes use of genetic 
resources in its development.35 The Guidelines also 
provide that user countries should take into account 
measures to promote disclosure of the origin of 
genetic resources and the origin of knowledge, 
innovations, and practices in IP applications (16.d.ii).   
The aim of disclosure is to help track compliance 
with prior informed consent and the mutually agreed 
upon conditions on which access to genetic resources 
was granted. Furthermore, at the VII Conference of 
the Parties, in CBD Decision VII/ 19, aspects related 
to disclosure of the origin of genetic resources in IP 
applications were identified, including aspects related 
to the certificate of origin or source/legal provenance. 
CBD Decision VII/19 advocated for (a) model 
provisions on proposed disclosure requirements; (b) 
practical options for IP rights application procedures 
with regard to the triggers of disclosure requirements; 
(c) options for incentive measures for applicants; (d) 
identification of the implications for the functioning 
of disclosure requirements (e) IP-related issues raised 
by proposed international certificate of 
origin/source/legal provenance.36 
DO  may include information of: (a) genetic 
resources used in developing claimed inventions;  
(b) the country of origin of such genetic resources;  
(c) associated traditional knowledge used in such 
development; (d) the source of such associated 
genetic resources and traditional knowledge; and  
(e) evidence of prior informed consent.37 
The rationale for DO is to prevent misappropriation 
of genetic resources, and ensure compliance with 
prior informed consent and benefit sharing 
obligations.  DO has not only been justified within the 
patent system, but also outside patent regime. The 
introduction of DO in patent systems aims to improve 
examination and to determine inventorship.38 On the 
other hand, the obligation of DO outside the patent 
system aims at ensuring compliance with prior 
informed consent (PIC) requirements and to promote 
effective benefit sharing arrangements.39 The 
arguments justifying the DO within the patent system 
has been put as follows: 
”a legally binding obligation to disclose the source 
and country of origin of biological resources and/or 
traditional knowledge used in inventions will guide 
the patent examiners in ensuring that all relevant 
prior art information is available to the patent 
examiners. Disclosure will also be relevant in helping 
patent examiners determine whether the claimed 
invention constitutes an invention that is excluded 
from patentability under Article 27 Paragraphs 2 and 
3 of the TRIPS Agreement. Further, disclosure would 
serve as part of a process to systematize available 
information of biological resources and traditional 
knowledge that will continuously build the prior art 
information available to patent examiners and the 
general public. In addition to matters relating to prior 
art, patentability and exclusions to patentability, the 
disclosure requirements will also be useful in cases 
relating to challenges to patent grants or disputes on 
inventorship or entitlement to a claimed invention as 
well as infringement cases. It has already been shown 
in the TRIPS Council that patent challenges involve a 
great cost in terms of time and resources, and are not 
a suitable option for developing countries. Patent 
grant challenges, cases on inventorship or entitlement 
as well as infringement cases form an important 
component of processes that ensure patent quality. In 
this regard, it is noteworthy that disclosure 
requirements of various types are already an accepted 
norm in international patent law practice”.39 
 
The Function and Scope of Disclosure of Origin in Patent Law 
The DO was initially associated with international 
environmental law; but in modern times but its 
relevance is generally associated with patent law.17 
Correa notes that DO enhances the substantive 
examination of patent applications that are based on 
genetic materials and knowledge of their resources. 
The disclosure may facilitate the determination of 
prior art by providing useful information to the 
examiner. The information supplied may also help to 
identify possible cases of misappropriation of 
biological materials and facilitate actions to challenge 
the validity of wrongly granted patents.40 In essence, 
disclosure ‘functions to help ensure that inventions 
that meet the criteria of novelty, inventive step and 
industrial application are granted exclusive rights, and 
to exclude from patentability those that do not meet 
these criteria, as well as to make technical information 




available to ABS law, by requiring inventors to 
include and make public relevant information about 
important inputs obtained from provider countries.41 
Disclosure ensures the transparency by allowing 
national authorities that grant access to genetic 
resources to track the use of these resources in patent 
applications and deeds. Disclosure is at the core of the 
policy rationale and the practical operation of the 
patent system. Disclosure illustrating technical and 
legal information, often to exacting standards, is 
central to the operation of the patent system because 
the grant of a patent and the effective exercise of 
patent rights, are based on the principle of adequate 
disclosure. The patent system involves making 
publicly available a detail of legal, administrative and 
technological information, in an accessible format. 
The disclosure in patent applications is used as a 
resource for those monitoring the use of genetic 
resources in inventions, including where the nature of 
genetic resources derived from and a matter of 
existing practice, disclose significant information 
concerning genetic resources. 
DO obligation ensures that all relevant prior art 
information is available to patent examiners, and 
enables examiners to determine whether the claimed 
invention is excluded from patentability under Article 
27(2) and (3) of the TRIPS Agreement. DO 
obligations require inventors to disclose sources of 
genetic resources where such resources have been 
identified as inventive contributions. While naturally 
occurring GR are clearly not inventions, traditional 
knowledge that triggers the research leading to the 
patenting associated with GR may well qualify as an 
‘inventive contribution’ that needs to be declared. 
According to one authority on United Kingdom, “the 
generation of the idea or avenue for research, that is 
the formulation of the problem to be addressed, has 
also been treated as inventive”.42 The extent to which 
traditional knowledge may constitute invention 
contribution however depends on national legislation.  
WIPO notes: 
“Where the inventive activity of a patent applicant 
uses the (traditional knowledge) (TK) as a lead or a 
hint, and the TK is not part of the inventive process as 
such, then TK holders or TK providers may not be 
considered a co-inventor as such. Outcomes in this 
area and the distinctions between inventive and non-
inventive contribution may also vary according to the 
way general principles are applied in respective 
national legal systems. Potentially, what is considered 
an inventive contribution in one jurisdiction may not 
be considered as such in another jurisdiction, 
meaning that the obligation to identify each inventor 
could in some borderline cases differ in different 
countries – cases in which TK provided a directly 
relevant lead or constituted the first step of the 
inventive process could figure among such borderline 
cases. This eventuality is illustrated by Rule 4.6 (c) of 
the Regulations under the PCT, which provides for 
the possible need for a request filed with an 
international application to “indicate different 
persons as inventors where, in this respect, the 
requirements of the national laws of the designated 
States are not the same”.43 
 
Incorporation of DO within the Indonesian Patent System 
Regulation of DO in the Indonesian Patent Act 2016  
As noted earalier, DO was formally introduced in 
the sixth Conference of Parties (COP) to the CBD and 
adopted in the Bonn Guidelines in 2002.44 Indonesia 
ratified the United Nations Convention on Biological 
Diversity (UNCBD), and enacted it own Act No. 5 of 
1994. Not only was the Convention ratified to achieve 
its three main objectives, namely (i) the conservation 
of biological diversity, (ii) sustainable use of 
components; and (iii) fair and equitable sharing of 
benefits arising from use of genetic resources, but also 
it is in line with Indonesia’s national food security 
interest and general economic development as 
discussed earlier in this paper.   
While the DO framework adopted in the CBD and 
Bonn Guidelines are not mandatory, Indonesia 
considered it prudent to legislate for a patents regime 
that incorporates DO.  Thus, The Indonesian Patent 
Act, 2016 adopted DO for patent applications. The 
framework introduced under The Indonesian Patent 
Act, 2016 does not only deal with information about 
origin, but also compliance with national access laws, 
including effective fair and equitable benefit sharing. 
The Indonesian Patent Act, 2016 replaced Law No. 14 
of 2001 on Patents and was meant to bring clarity to 
the issue of Patents.  Relevantly on the issue of GR, 
the Act provides an obligation to specify the origin of 
genetic resources and or traditional knowledge in the 
descriptions of those inventions derived from either 
source: (i) to avoid any potential contesting claims by 
other countries; and (ii) to support access benefit 
sharing for Indonesia. 
In the preamble, The Act acknowledges that 
patents are granted as intellectual property by the state 




to inventors and that patents have ‘a strategic role in 
supporting the development of the nation and promote 
the general welfare’. Interestingly enough the 
preamble also states that ‘technological development 
in various fields has been so rapid that it is necessary 
to increase the protection of inventors and patent 
holders.  What is interesting about this statement in 
the preamble is that the focus appears to be on the 
‘protection of inventors and patent holders’ without 
reference to Indonesian interests as a host or source 
state.  On GR and the issue of disclosure, the Act says 
very little.  Indeed only Article 26 directly mentions 
GR and DO directly: 
(1) If the Invention relates to and / or originates 
from genetic resources and or traditional knowledge, 
it have to be mentioned clearly and correctly the 
origin of genetic resources and / or knowledge 
traditional in the description. 
(2) Information on genetic resources and / or 
traditional knowledge as referred to in Paragraph (1) 
shall be established by an authorized institution 
recognized by the government. 
(3) Distribution of results and / or access to 
utilization of genetic resources and / or traditional 
knowledge as referred to in paragraph (1) shall be 
carried out in accordance with the laws and 
regulations international treaties in the field of 
genetic resources and traditional knowledge. 
There are other sections of the Act that relate 
indirectly to GR. For instance under Article 93: 
(1) The Minister may grant a compulsory license 
for the manufacture of pharmaceutical products 
patented in Indonesia for the treatment of human 
disease. 
(2) The Minister may grant a compulsory license 
for the import of the procurement of pharmaceutical 
products patented in Indonesia but have not been able 
to be produced in Indonesia for the treatment of 
human disease.  
(3) The Minister may grant a compulsory license 
for export of pharmaceutical products patented and 
manufactured in Indonesia for treating human disease 
by demand from developing countries or 
underdeveloped countries 
However the effectiveness of this provision will 
depend on whether the inventor patented the product 
in Indonesian. As a party to the CBD has to enact 
laws to give effect to mainly in relation to: (a) the 
conservation of biological diversity, (b) sustainable 
use of its components, and (c) fair and equitable 
sharing of benefits arising from use of genetic 
resources.  Under the Convention, Indonesia has the 
sovereign right to regulate access to genetic resources 
in its territories and to adopt measures to regulate 
access and sustainable use and benefit sharing of 
genetic resources found within its territory (Article 
15.7). The Indonesian Patent Act, 2016 is thus 
consistent with the rights and obligations of Indonesia 
under the CBD. Other laws such as Article 33.3 of the 
Indonesian Constitution and Articles 7.1, 7.2 and  
7.3 of the Indonesian Plant Variety Protection Act 
2000 also complement The Indonesian Patent Act, 
2016.  In addition, the 2017 Ministerial Regulation of 
Research and Technology, and Higher Education 
issued a regulation to control the utilization of local 
genetic resources and prevent misappropriation.  
 
Model of Imposing Disclosure of Origin 
DO for genetic resources can be mandatory or 
voluntary, direct and indirect. Disclosure of origin 
requirements could be direct (mandatory and 
enforceable through a loss of patent rights), indirect 
(mandatory but enforceable only through means other 
than the patent system), and voluntary or on 
permissive basis.45 According to Graham Dutfield, 
voluntary DO is the least burdensome. It encourages 
the disclosure of genetic resources to an invention 
being patented without any penalties. Given the 
voluntary nature, noncompliance with such disclosure 
requirements gives rise to no legal consequences since 
it would not disqualify the patent application from 
being accepted, being granted, or being subsequently 
enforced. On the other hand, with mandatory DO, the 
burden of compliance is placed on patent applicants, 
and the failure to disclose or dishonest disclosure will 
could lead to the rejection of the patent application or 
if granted it would not be enforceable, or it can be 
revoked with possible criminal sanctions.46 The role 
of the provider country is to monitor compliance and 
take legal action in cases of non-compliance. 
The DO can also be substantive or procedural in 
nature. The DO is procedural where it is reviewed at 
stages of IP application process for completeness and 
for formal compliance with specified procedures.  It is 
substantive if compliance is requited in determining 
validity or legality of the application.  In the case of 
plant varieties, The International Union for the 
Protection of New Varieties of Plants (UPOV 
Convention 1991) UPOV does not consider DO as a 
requirement or an additional condition for plant 




varieties protection because based on Article 5, the 
UPOV has established specific requirements to grant 
a plant breeder right where the variety is new, distinct, 
uniform and stable.47 The UPOV stipulates that plant 
breeders’ rights shall not be subject to different or 
further conditions, provided by national formalities.  
Although Indonesia has not ratified the UPOV 
Convention, similar criteria for protection of plant 
varieties have been stipulated based on  the ‘new, 
distinct, uniform and stable’ elements (Article 2.1 of 
Indonesian Plant Variety Protection Act). In addition, 
according to Article 30.1 of Indonesian Plant Variety 
Protection Act, substantive inspection is to be 
conducted by the examiner who shall investigate 
whether a variety is new, distinct, uniform and stable. 
While the Act appears silent on disclosure, the 
examiner is allowed to demand information related to 
genetic resources because Article 33.2 of Indonesian 
Plant Variety Protection Act stipulates that in 
conducting the inspection, the PVP office may request 
information from other institutions from within the 
country or abroad.   
In the case of patent applications, substantive 
requirements must be met in order to obtain a grant of 
a patent of IP rights, while failure to comply with 
requirements on DO may have severe consequences 
such as cancellation of IPR, refusal to process 
applications, revocation of patents, or placing IP in 
joint ownership or possible criminal sanctions.  The 
Indonesian legislation is ambiguous with respect to 
DO requirements. In fact, unlike ‘novelty’ or ‘non-
obviousness’ as patentability requirements that 
concern the substance, i.e., the very essence of a 
inventive activity, DO seems to be merely an 
accessory, which relates to the invention collaterally 
under the Act. Similarly, the Act stipulates the 
patentability of invention based on the criteria of ‘new 
or inventive steps’ related to the industry (Article 3 of 
The Indonesian Patent Act, 2016). DO obligation is 
not made a part of substantive patentability 
requirements under Article 3 of The Indonesian Patent 
Act, 2016.  
In order to enforce the compliance with DO 
requirement, there are options for sanctions against 
noncompliance including patent invalidity, 
unenforceability of a patent, transfer of patent right, 
imposition of benefit sharing arrangements, criminal 
sanctions, or rejecting patent processing. Indonesia 
has stipulated legal consequences for failure of 
compliance of DO requirement under Article 58.1 48 
of The Indonesian Patent Act, 2016. This provision 
affirms the interconnection of the obligation to 
provide DO with the legal consequences that failure 
to satisfy any of these requirements will result in the 
rejection of a patent application. In addition, under 
Article 62 Paragraph (10) of The Indonesian Patent 
Act, 2016, the failure to satisfy DO requirements also 
affects the judgement of application withdrawal. 
Furthermore, Article 132 (1) provide legal 
consequences by terminating the patent validity based 
on a court decision if the terms of patents derived 
from genetic resources and or traditional knowledge 
do not satisfy the provisions of DO as referred to 
Article 26. Under Articles 67 and 68 of The 
Indonesian Patent Act,  2016, applicants can file an 
objection to a rejection of patent application with the 
Appeal Commitee of the Directorate General of 
Intellectual Property49 as a post-grant administrative 
challenge proceeding. Alternatively, a judicial action 
can also be brought as substantive review of a 
decision on invalidity based on Article 130 of the Act.  
Since DO under the  Indonesian Patent Act  2016 
may be reviewed for substantive requirements, it is 
also essential to establish mandatory DO requirements 
in order to prevent misappropriation of genetic 
resources, to prevent misuse of IP system, and to 
promote compliance with CBD access and benefit-
sharing requirements, reflecting the interconnection of 
the CBD regime with the IP regime. Mandatory DO 
requirements may be useful in improving substantive 
examinations and in assuring the integrity of 
determinations under conventional IP legal 
requirements, in providing greater certainty as to the 
validity of granted rights or privileges, and in 
reducing the need for revocation of improperly 
granted IP. Such disclosure assists in identifying 
conditions and facilitating corrective actions where IP 
is wrongfully granted, or where access to genetic 
resources has been obtained without prior informed 
consent and equitable benefit-sharing. The DO is also 
necessary to prevent misappropriation of commercial 
benefits that are inappropriately obtained as 
consequence of applying, owning or transferring IP. 
 
Effectiveness and Challenges of Disclosure of 
Origin to Address Biopiracy 
Effective to Address Biopiracy 
Indonesian being rich in genetic resources has been 
always been an easy target for seed and biotechnology 
multinational enterprises engaging in agribusiness for 




the purpose of bio-piracy. The obligation of DO may 
contribute to address a major concern of developing 
countries about the biopiracy of genetic resources and 
traditional knowledge (TK),35 especially in patent. DO 
paves the way for monitoring the respect of the rules 
on utilization, commercialization of generic resources, 
including access and benefit-sharing, where such rules 
are in place. Disclosure may stop biopiracy or the 
misappropriation of genetic resources, or granting of 
“bad patents.50 Bad patents concern ideas that are only 
of minimal variations on existing knowledge or hardly 
new. According to Correa, without further 
improvement, there has been extensive documentation 
of patent being sought over plant genetic resources 
“as they are”. There were many incidents of bad 
patents such as US Pat No. 5,304,718 on quinoa 
granted to researchers of the Colorado State 
University, US Plant Pat No. 5,751 on Ayahuasca - a 
sacred and medicinal plant of the Amazonia, and on 
products based on plant materials and knowledge 
developed and used by local/indigenous communities 
such as the cases of the Neem Tree, Kava, Barbasco, 
Endod and Turmeric, among others.51 
The misappropriation of GR and the forgone 
benefits derived from their utilization continues to elicit 
serious misgivings among the biodiversity rich 
countries, including in Indonesia. A series of cases of 
misappropriation of genetic resources have solidified 
the tensions between CBD objective of promoting the 
fair and equitable benefit sharing and the types of 
incentives established by IP rules under TRIPS.  
According to Article 8 (j) of the CBD, there is a 
commitment to respect, preserve and maintain genetic 
resources and traditional knowledge. In relation to 
inventions directly based on genetic resources or 
traditional knowledge, there is an obligation for patent 
applicants to disclose and declare the specific source of 
such resources, if knowledge, innovations and practices 
of traditional knowledge and genetic resource are used 
on the invention. However, the realization of these 
CBD objectives has faced tremendous challenges. The 
CBD objective has proven difficult to implement in an 
effective manner since the use of genetic resources is 
increasingly linked with international trade. Genetic 
resources users such as individuals, researches and 
firms that develop innovative applications based on 
such resources, often are located outside the country of 
origin of these resources, thus it is arduous to 
implement the obligation of DO including  
benefit sharing. 
Benefit sharing and DO have reciprocal 
relationships in which benefit sharing cannot occur if 
patent-holders do not disclose the geographical 
origins of the biological resources that they used for 
their inventions. Many biopiracy cases have persisted 
because of an information problem that exists at the 
patent application level. In patent applications, those 
engaging in biopiracy often do not identify the 
geographical origins of genetic resources materials, 
and when patent offices approve the applications, 
these patent-holders could enjoy the fruits of their 
products for a long period without encountering  
a challenge. 
DO at the patent application stage is essential 
because it gives prompt notice to those who want to 
challenge the patent by examining requirements of 
patentability. According to Article 27.1 of TRIPS, key 
criteria for obtaining a patent shall be available for 
any inventions, whether products or processes, in all 
fields of technology provided that they are new, 
involve an inventive step and are capable of industrial 
application. 
Article 3.1 of The Indonesian Patent Act, 2016 has 
also adopted similar criteria by stipulating that a 
patent shall be granted to an invention, which is 
novel, involves an inventive step and is susceptible of 
industrial application. According to Article 5.1.of The 
Indonesian Patent Act, 2016, an invention shall be 
considered novel, if at the date of filing of the 
application, the invention is not the same with any 
previous technological disclosure. Moreover, an 
invention shall be deemed to involve an inventive step 
if the invention does not constitute something that is 
obvious to a person skilled in the art (Article 7.1. of 
the Act). The evaluation of whether or not an 
invention constitutes something that is obvious must 
be made taking into account the state of the art at the 
time the application is filed or which has existed at 
the time the first application was filed, in case the 
application is filed on the basis of a Priority Right 
(Article 7.2. of the Act). Furthermore, an invention 
shall be considered susceptible of industrial 
application if it can be implemented in the industrial 
as described in the application (Article 8 of the Act).  
In cases of biopiracy, complainants have often 
challenged the lack of real novelty frequently due to 
existing art in the form of common/traditional 
knowledge or documented prior use. In Indonesia, the 
consideration of novelty is based on the criteria as to 
whether at the date of filing, the invention is not the 




same with any previous “technological disclosure”. 
Article 5.2. of the  Indonesian Patent Act 2016 further 
stipulates that technological disclosure as referred to 
is one which has been announced in Indonesia or 
outside Indonesia by writing, by a verbal description 
or by a demonstration, or in other ways, which enable 
a skilled person to implement the invention before the 
Filing Date, or the Priority Date.  
In Indonesia, DO is relatively new; therefore the 
effectiveness of this measure remains unproven, and 
needs other measures that can be just as valuable in 
preventing biopiracy. In addition, DO can only deal 
with a small part of the problem of genetic resource 
misappropriation, and so a range of other measures is 
also needed. The implementation of a workable DO 
regime with prior informed consent, ABS legislation 
and other measures such as certificates of origin, 
systems to track genetic resources, or monitoring and 
controlling system within sectoral fields, will be the 
effective way of preventing biopiracy. 
 
Challenges of Disclosure of Origin 
Regulatory Challenge: Lack of Clarity  
Although Indonesia has imposes an obligation of 
DO and benefit sharing under Article 26 The 
Indonesian Patent Act, 2016, further provisions are 
needed to enforce the regulation since Article 29 of 
the Act mandates that further provisions concerning 
the terms and procedures for filing the patent 
application, including the patent requirements such as 
DO and benefit sharing shall be regulated by a 
Ministerial Regulation. Since the Ministerial 
Regulation has not been adopted yet, the scope of 
procedural, institutional and legal consequences 
relating to non-compliance of DO remains unclear. 
Indonesia has not yet specified many details, 
including the circumtances leading to the 
requirements for disclosure, content of information, 
the timing, format and level of detail required, and the 
consequences of a failure to disclose. There is also no 
clarity regarding how applicants must identify where 
the material is obtained, the person or organization 
providing it, any genetic resources used, etc. In 
addition, there is no regulation about the obligation of 
patent applicant to enter into an agreement of access 
and benefit sharing with the appropriate rights-holder 
or provide prior informed consent first before lodging 
a patent application.  
Article 3 and Article 54 of The Indonesian Patent 
Act, 2016 confusingly scramble the substantive and 
procedural requirements by incorporating DO into the 
measures of substantive assessment of patent 
application. The substantive requirement of patent has 
been set under Article 3, however, Article 54 also 
shuffles other requirements (including the DO 
regulated under Article 26) as one of substantive 
requirements for granting patent. 
The next regulatory problem is about unclear 
definition of the genetic resources involved: whether 
genetic resources disclosure required for the use of a 
product is several generations away from the original 
genetic resource, or a synthetic compound derived 
from lead compounds discovered in nature. The lack 
of clarity over terminology and definitions in this 
regard creates greater legal uncertainty and  
legal loopholes.  
With respect to the consequences for non-
compliance of DO measures, there are several options 
open to Indonesia. The options include civil or penal 
liabilities, administrative sanctions, suspension of 
application processing, revocation or annulment of 
rights when the submitted information required in DO 
is insufficient or false, or the requirement that patent 
rights should be jointly owned or transferred either 
partially or completely.52  Indonesia can adopt any of 
these options. However The Indonesian Patent Act, 
2016 only narrowly provides that failure to satisfy any 
of the DO requirements will result in administrative 
consequences such as the rejection of a patent 
application (based on Article 58.1), or lead to 
application withdrawal (Article 62 Paragraph (10) or 
terminating the patent validity (Article 132 (1)(b)).  In 
addition, it is also unclear what is meant by 
termination of patent rights under Article 132 (1)(b). 
In specific terms, it is not clear whether the revocation 
or annulment of patent rights is the result of when the 
submitted information required in DO is insufficient 
or false. 
Indonesia should consider other measures for non-
compliance of DO requirements by including not only 
administrative penalties (rejection and withdrawal of 
patent application) and legal sanctions (terminating of 
patent rights), but also civil or penal liabilities, 
suspension or pending of application processing, clear 
revocation or annulment of rights, or transfer of patent 
rights partially or completely, or repayment of any 
benefits received. It is also necessary to develop other 
measures outside the patent system such as unfair 
competition, environmental law, consumer protection, 
etc. In other words, Indonesia still needs to provide 




opportunities to rectify disclosure failures and 
remedies tailored to the scope and nature of  
the failures.  
 
Poor Definition of ‘Origin’  
‘Genetic resources’ is defined very broadly, to 
include "any biological material which contains genes 
and/or metabolic material that may be derived from 
genes. They fall within the scope of the Nagoya 
Protocol whenever they are used for research or 
product development”.53 This definition offers little 
practical guidance.  It is not clear whether the ‘origin’ 
refers to the resource’s country of origin or to its 
source, i.e. the country from which the resource is 
received. It is also not clear whether the concept of 
origin refers to the country that contributes or 
provides the resource’s geographic origin, or to 
combination of different options, such as the 
disclosure of the source together with, if known, the 
resource’s country of origin. It is often difficult to 
determine the origin of a resource, in cases in which a 
resource comes from an ex situ collection e.g. a 
botanic garden and was collected many years ago.  
The Indonesian Patent Act, 2016 needs to provide 
clarity on this issue since it is central to disclosure. 
 
The Absence of Clear Access and Benefits Sharing Regulation 
Access and benefits sharing (ABS) are at the heart 
of disclosure and the prohibition of biopiracy.   
Indonesia has no clearly defined ABS regulation in 
spite of adopting the Indonesian Patent Act, 2016. A 
comprehensive ABS regulation is an essential element 
to DO. A good ABS regulatory framework can 
provide prior informed consent to get access to 
genetic resources. Effective DO will help to promote 
ABS and prior informed consent in Indonesia because 
such information would allow the government to 
check whether the access legislation had been 
complied with and if prior informed consent had  
been obtained.  
 
Inadequate Human and Other Resources Capacity   
DO protocols as envisaged under The Indonesian 
Patent Act, 2016 are relatively new to Indonesia. The 
reality is that the state lacks the requisite human 
resources capacity to police or manage an effective 
DO regime. The government and its institutional 
agencies lack experience in arranging and developing 
DO and benefit sharing mechanisms. Accordingly, 
fair and equitable sharing of benefits arising out of the 
use of genetic resources have proven difficult to 
implement in an effective manner, as the use of 
genetic resources is increasingly linked with 
international trade which sometimes requires high 
levels of expertise in negotiations and drafting of 
necessary regulations.  
Indonesian bureaucratic procedures are inefficient 
and slow at the best of times.  It is a fair assumption 
that the interdiction of DO is likely to impose 
additional burden to patent system with increased 
workload on patent examiners.   In any event, The 
Indonesian Patent Act, 2016 and related regulation do 
not articulate clearly what the role of the patent 
examiners should be in respect of DO.  It is not clear 
whether they will only file the information received or 
also check its veracity; or they must cooperate with 
other institutions. Therefore, some argue that it is 
wrong in principal to try to deal with DO and ABS 
issues within the patent system, since these are alien 
to patent law in Indonesia. 
Another problem is the cost of implementing DO 
and ABS regulation, including the cost of establishing 
systems to monitor and enforce compliance. This can 
be considerable, particularly in Indonesia where 
budget, expertise and institutional capacity are often 
limited. It cannot be denied that development of DO 
and ABS system will be costly in Indonesia because 
of the need to introduce new further legislation, 
establish monitoring institutions, train staff, develop 
appropriate system, etc. In fact Indonesia still lacks 
institutional capacity and the expertise to implement 
the necessary legislation. The capacity to monitor 
patent applications and the use of genetic resources is 
also insufficient. The effective degree of co-
ordination between authorities as well as new 
institutional arrangements is still also questionable.  
As indicated earlier Indonesia lacks the human 
resources capacity to monitor or police DO 
effectively. However even if misappropriation is 
detected, it is doubtful that Indonesia has the 
economic and financial capacity to invalidate patents 
particularly in foreign jurisdictions, considering the 
long and costly process involved, and the need to 
study the measures of other user countries. Some non-
governmental organizations (NGO) have helped in 
tracking bad patents over genetic resources, however 
it is uncertain the extent to which they may continue 
to do so. In addition, if a fallaciously granted patent is 
found, who will be eligible to initiate invalidation 
procedures with given the costs involved in any 
potential litigation? 




Challenges with Ensuring Community Benefits  
Article 26 (3) of The Indonesian Patent Act, 2016 
stipulates that benefit sharing and access to utilization 
of genetic resources shall be carried out in accordance 
with the laws and regulations and international 
treaties in the field of genetic resources.  There is no 
doubt that local communities are legitimate 
stakeholders in local genetic resources and are entitled 
to benefits sharing from any inventions based on their 
local resources.   Indonesia does not have any 
systematic policy or procedure for determining 
ownership of resources. It is not clear with whom 
benefits should be shared because many genetic 
resources are found in more than one geographical 
origin in the country, and may have to be shared by a 
number of communities or peoples. In its current 
state, the notion of ensuring community benefits 
envisaged in The Indonesian Patent Act, 2016 only 
remains on paper and needs clarity.   
 
Lack of Clarity on Institutional Agencies  
Under Article 26 (2) of The Indonesian Patent Act, 
2016, the information on genetic resources as referred 
to in DO shall be established by an authorized 
institution recognized by the government. Given that 
the applicants are likely to have to show they were 
authorized by a relevant national institution to access 
the resource before they obtained it, it is unclear who 
the relevant national bodies will be and what 
constitutes such authorization. It is unclear and often 
difficult to determine who is the authorized institution 
or legal authority to establish conditions and 
mechanism provided in DO requirements and ABS. It 
is also unclear which institutions are competent to 
authorize the source to provide access and to 
determine the legality of the conditions established for 
access and equitable benefit-sharing, including 
provisions for approval and for defining 
misappropriation.  
 
Lack of Clarity on Links between Genetic Resource and 
Invention  
A further problem is the difficulty to identify the 
link between genetic resource and an invention that 
would trigger disclosure since current Indonesia 
legislation only vaguely defines this. Indonesia has 
not determined how the link between an invention and 
genetic resource can be meaningfully related, how 
closely the invention must be to such resources, 
whether the invention makes use of biological 
material involving components of biodiversity. It is 
also unclear how to define the sort of genetic 
resources involved, whether disclosure is required for 
the use of a product if it was several generations away 
from the original genetic resources.  
From a technical point of view, many questions 
still remain to be answered.  For instance, it is not 
clear if standardized terminology and certain specific 
content should be used, what sort of information 
should be submitted, or how the information should 
be presented. It is also questionable whether the mere 
disclosure of information will be adequate to comply 
with the DO requirements, or should the application 
be accompanied by a declaration or proof of origin 
from the applicants, or by some form of authorizing 
evidence to prove compliance with access laws, such 
as a copy of the access contract or other required 
documents.  
 
Issue of Timing 
The time for presenting the DO is also unclear.  
The regulations do not indicate when the information 
be examined and by whom, or when access to genetic 
resources should be considered to have been duly 
authorized. It is not easy to determine the exact time 
of required disclosure because of the complexity and 
length of the research process. 
Although DO is mandatory in Indonesia, there is 
no checking or monitoring system for patent 
applications such as monitoring resource use or 
preventing resource misappropriation. In addition, no 
notification system has been established in Indonesia. 
This means that little progress has been made in 
enhancing the transparency of the patent system. The 
feasibility of DO both with respect to the ability of 
patent applicants to comply and of patent offices to 
check compliance, particularly with requirements to 
meet the prior informed consent and ABS legislation 
is also questionable. To date DO together with prior 
informed consent and ABS requirement have been 
seen as a burden, either for applicants or patent 
offices. Lack of clarity of the legislation has meant 
that the patent office has not yet utilized this measure 
and these limited experiences underline the need for a 
well-established legislation.  
 
Findings and Suggested Solutions  
Prioritizing an Effective Regulatory Framework   
With its mega biodiversity Indonesia is vulnerable 
to biopiracy.  What is evident from the current 
Indonesian policies and regulations is that the 
country’s regulatory framework to protect its GR does 




not adequately deal with the prevention of biopiracy. 
If Indonesia is to combat biopiracy, then it must 
create further regulation to effectively implement the 
provisions on DO and the related issues since DO 
alone will not be able to solve misappropriation of 
genetic resources and cannot be regarded as the only 
panacea. To achieve an effective DO system, it is 
necessary to regulate procedural, institutional and 
other infrastructural measures such as the standards, 
procedures, further requirements, mechanism, 
monitoring and evaluating system, institution that 
authorizes to the implementation, remedies, etc. 
Further regulation should specify details of 
circumstances for disclosure, information content, the 
timing, format and level of detail required, including 
obligation of patent applicants to compulsorily 
provide PIC and enter into an access and benefit 
sharing agreement  with the appropriate rights-holder 
first before applying for patents.  
It is important to develop a strong and user-friendly 
legislation with a two-tiered system of approval for 
access to genetic resources. A two-tiered system 
could be established with: (a) non-restrictive licensing 
for non-commercial research, (b) a restrictive policy 
for commercial users of resources.  In addition, codes 
of conduct for both industry and researchers would be 
a useful step, including a system for establishing 
bonafide research organizations that will collaborate 
with those wishing to utilize resources  
within Indonesia. 
 
Rethinking the Enforcement of DO Requirements  
In its current form, the DO regime lacks ‘teeth’. 
Noncompliance with DO does not attract severe 
sanctions. Failure to disclose could result in not 
granting a patent or withdrawing a patent. It is not 
enough to dissuade a patent applicant from 
nondisclosure.  To ensure DO compliance, Indonesia 
should develop rigorous enforcement mechanisms by 
considering civil liabilities, administrative sanctions, 
suspension of application processing, revocation or 
annulment of rights, transfer of patent rights either 
partially or completely, or repayment of benefits 
received, etc. Sanctions should not be established 
under patent system only, but effective, proportionate 
and dissuasive sanctions should be envisaged outside 
the field of patent law such as application of 
provisions on unfair competition penalties imposed on 
the non-compliant patent applicants/holders. To be 
more effective, Indonesia could also adopt the model 
of criminal sanctions applied in Article 81of the 
Patent Law of Switzerland which regulates that patent 
applicants could face additional criminal sanctions for 
lack of disclosure or false statements.54 
 
Standardization of Procedures   
In order to become effective, the way that the 
relevant information will be submitted to the patent 
offices must be standardized. This should be 
organized in a non-bureaucratic and cost-efficient 
manner. Recommendations on standardized model of 
DO could include: (a) the applicants should declare 
the country of origin or, if unknown, the source of the 
specific GR to which the inventor has had physical 
access which is still known; (b) the invention must be 
directly based on or derived from the specific GR; (c) 
the incentive for compliance and penalties for 
noncompliance; (d) simple notification procedure by 
the patent offices when they receive a declaration and 
it will be adequate to identify in particular the 
Clearing House Mechanism as the central body to 
which the patent offices should send the available 
information. In this sense, the high level of 
coordination between patent office and Clearing 
House Mechanism could be a useful avenue for 
notification and should be as simple as possible in 
order to avoid any unnecessary administrative burden 
for patent offices. The exchange of information 
should also be managed in a cost-effective way and 
without unnecessary additional charges imposed on 
patent applicants. 
 
Improvements in Stages of the DO Regime 
In a general context, to prevent GR 
misappropriation and support food security, Indonesia 
needs to improve various strategies of its DO regime 
to address: (a) the importance and value of GR 
through mainstreaming issues at every institutional 
and community level; (b) human resources capacity, 
including political, regulatory, and budgeting support 
from various stakeholders in the implementation of 
GR management; (c) inventory, identification, and 
publication of GR potential and value; (d) GR 
management impacts and benefits for various parties, 
especially the general public. 
 
National Anti Biopiracy Commission 
As noted earlier Indonesia’s mega biodiversity is 
vulnerable to biopiracy because of the country’s 
liberal visa system that encourages tourism which in 
enables and embolden ‘biopirating tourists’. The 
situation is exacerbated by the absence of an effective 




regulatory framework and supporting institutions. 
Given the importance of protecting GR in the national 
economy and the national food security strategy, it is 
essential to establish a national body charged with 
dealing with biopiracy.  Such a National Anti-
Biopiracy Commission could be established on a 
similar basis as the National Anti Biopiracy 
Commission of Peru which has successfully led 
Peru’s effort in enforcing anti biopiracy regulations.  
Established in 2004 The Commission has the 
following functions: 
a) Establish and maintain a register of biological 
resources and traditional knowledge. 
b) Provide protection against acts of bio piracy. 
c) Identify and follow up patent applications 
made or patents granted abroad that relate to Peruvian 
biological resources or collective knowledge of the 
indigenous peoples of Peru. 
d) Conduct technical evaluations of the above-
mentioned applications and patent grants. 
e) Issue reports on the cases studied.  
f) Lodge objections or institute actions for 
annulment concerning the above-mentioned patent 
applications or patent grants. 
g) Establish information channels with the main 
intellectual property offices around the world. 
h) Draw up proposals for the defense of Peru's 
interests in different forums.55 
The Indonesian Patent Act, 2016 in its current form 
does not provide the structured operational framework 
for any agency similar to the Commission in Peru. 
The Peruvian experience provides an important 
example for Indonesia in combating biopiracy. 
 
Spreading the Benefits and Building Capacity 
Indonesia must also establish effective mechanism 
for the restitution of the rights of communities and the 
model of benefit sharing for appropriation of genetic 
resources. Since benefit sharing is not limited to 
monetary sharing, Indonesia needs to seek the 
appropriate non-monetary form of benefits for the 
stakeholder communities. Benefits could be shared in 
other ways, for example, through training and 
capacity building since to ensure the effective 
implementation of ABS procedures and legislation, 
capacity building is needed within patent offices, 
customs and immigration, ABS institutions and more 
widely within many government and environmental 
institutions. Given that governmental authorities are 
relatively unfamiliar with the IP system, it is essential 
to develop IP understanding especially through 
training on issues related to IP including DO.  
This capacity building for human and technical 
resources of the environmental and IP authorities is 
crucial in order to review IP applications, identify the 
cases in which DO is mandatory, develop IP and 
genetic resources databases, compile and disseminate, 
as appropriate, information that can be useful for 
destroying the novelty of patent applications 
presented in other countries related to genetic 
resources, improve coordination with domestic and 
foreign IP and environmental offices. It is also 
important to exchange experience through internships, 
workshops, colloquium, etc. with countries that have 
established similar requirements and developed a 
significant practical experience that support the 
implementation of this instrument in Indonesia.  
Within civil society, public understanding and 
awareness of the IP system should be enhanced, 
especially among local communities by developing 
expertise among such communities to negotiate ABS 
agreements. The government should also prioritize the 
training of communities in negotiating skills and legal 
education, to help them to establish fair access 
agreements. There is also a need for further awareness 
raising and education about DO, prior informed 
consent and benefit sharing obligations among small 
firms and sectors of the research community.  
 
Conclusion 
Indonesia is a land blessed with significant 
biodiversity that attracts biopiracy in the absence of a 
strong and effective DO enforcement mechanism. In 
general, DO plays an important role in protecting 
plant genetic resources. It helps in (a) identifying 
scientific or commercial use; (b) identifying rights 
holders; (c) identifying the existence of prior art; (e) 
facilitating the monitoring and enforcement of rights; 
(f) preventing illegal and/or unauthorized use; (g) 
preventing the grant of wrong patents; and (h) 
promoting equitable benefit sharing. The adoption of 
The Indonesian Patent Act, 2016 was a step in the 
right direction in enforcing DO and stopping 
biopiracy and achieving these objectives of DO. 
However DO remain a relatively new concept for 
Indonesia. The country has little practical experience 
in implementing and enforcing DO legislation. In its 
current form, The Indonesian Patent Act, 2016 lacks 
coherence and clarity in several areas. That makes it 
hard for the country to combat biopiracy 




meaningfully. The Indonesian Patent Act, 2016, 
therefore needs improvement.   
As part of the improvements needed to enforce DO 
and combat biopiracy effectively, Indonesia should 
consider the establishment of a National Anti 
Biopiracy Commission. The commission could 
provide a coordinating platform and oversee the 
effective implementation of The Indonesian Patent 
Act, 2016 provisions on DO.  More importantly it 
could also provide an incubating channel for building 
capacity in policing biopiracy.   While The Indonesian 
Patent Act, 2016 is clearly a step in the right 
direction, it does not appear to have a well-defined 
destination or objective in terms of combating 
biopiracy.  A National Anti-Biopiracy Commission 
can provide clearer objectives and ensure a more 
effective fight against biopiracy.  
Indeed the protection of GR is a cross cutting 
national issue for the country given its relevance to 
agribusiness, food security and the general economy. 
An effective DO system must therefore necessarily 
involve coordination between state agencies from the 
environment to agriculture and economic planning 
and community stakeholders who may be traditional 
knowledge holders. The objective in strengthening the 
DO system is not to deter researchers, inventors and 
investors, but to enhance transparency, and to 
discourage misappropriation of GR.   
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